Neurotronic Reveals Initial Clinical Results of Multi-Organ Denervation for Treating Type 2 Diabetes and Hypertension

Written by Emily J. Thompson, Senior Investment Analyst

BEST%

Source: Newsfilter

Updated: Oct 24 2025

0mins

Source: Newsfilter

Upcoming Presentations: Neurotronic, Inc. will present groundbreaking results from the NECTAR III and NECTAR IV trials at TCT 2025, showcasing the first clinical outcomes of the Neuviant™ Multi-organ Denervation system for treating type 2 diabetes and hypertension.
Study Details: The trials evaluated the safety and efficacy of hepatic and renal denervation in patients with uncontrolled type 2 diabetes and hypertension, with presentations scheduled for October 26 and 27, 2025, in San Francisco.
Innovative Therapy: The Neuviant MDN procedure involves delivering ethanol via catheter to disrupt overactive sympathetic nerve pathways, aiming to lower blood sugar and blood pressure in patients.
Company Background: Founded in 2015, Neurotronic focuses on pioneering multi-organ denervation therapies for complex cardiovascular and metabolic diseases, including type 2 diabetes and hypertension.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Neurotronic Reveals Initial Clinical Results of Multi-Organ Denervation for Treating Type 2 Diabetes and Hypertension

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

D-Wave Quantum (QBTS) Shares Surge 211%, Outperforming Market Indices

Storage Stocks Surge Over 200% in 2025, Led by Sandisk's 559% Gain

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch